Drainage Amount for Removal of Thoracostomy Tube

NCT ID: NCT00575198

Last Updated: 2017-06-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

280 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-12-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether chest tubes can be safely removed without considering how much fluid is draining through the tube.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Thoracostomy tubes are routinely used to drain the pleural space of fluid and gas to optimize pulmonary mechanics. Clinicians frequently postpone removal of thoracostomy tubes if the drainage from the tube exceeds a specific volume threshold for the prior 24 hours. However, there is substantial variability in the drainage volume threshold that different clinicians use, and no threshold has been established as clearly superior to any other. Removing tubes independently of the drainage volume may result in a greater risk of pleural effusion or pneumothorax requiring an invasive drainage procedure. However, removing tubes independently of the drainage volume might also expedite recovery by allowing earlier removal of the tube, thus diminishing pain and increasing patient mobility.

Thoracostomy tube management practices, including the drainage volume threshold used, may be dissimilar for different types of disease processes, so this study will be restricted to patients who required a thoracostomy tube for treatment of traumatic injury.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumothorax Pleural Effusion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

No drainage threshold

Group Type EXPERIMENTAL

No drainage threshold

Intervention Type OTHER

Removal of the thoracostomy tube independently of the amount of fluid that drained from the tube in the prior 24 hours

2

Drainage \<2 mL/kg

Group Type ACTIVE_COMPARATOR

Drainage <2 mL/kg

Intervention Type OTHER

Removal of the thoracostomy tube only if the drainage from the tube in the prior 24 hours is less than 2 mL/kg of the patient's ideal body weight

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No drainage threshold

Removal of the thoracostomy tube independently of the amount of fluid that drained from the tube in the prior 24 hours

Intervention Type OTHER

Drainage <2 mL/kg

Removal of the thoracostomy tube only if the drainage from the tube in the prior 24 hours is less than 2 mL/kg of the patient's ideal body weight

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Standard thoracostomy tube management

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Thoracostomy tube in place for \<72 hours
* Age at least 14 years
* Hospitalized for traumatic injury or elective operation

Exclusion Criteria

* Thoracostomy tube already removed from the pleural cavity of interest
* Mediastinal tubes
* Death expected within 48 hours
* Prisoner status
* Severe congestive heart failure
* End-stage liver disease
* End-stage renal disease
* History of or suspected empyema involving the pleural cavity of interest
* History of or anticipated need for pleurodesis of the pleural cavity of interest
* Malignant pleural effusion
* Pregnancy
* Previous participation in this study
* Thoracostomy tube drainage already \<2 mL/kg
Minimum Eligible Age

14 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of California, Davis

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Garth H Utter, MD MSc

Role: PRINCIPAL_INVESTIGATOR

University of California, Davis

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California, Davis, Medical Center

Sacramento, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

200715709

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.